taladegib: Clinical Trials

3 trials of taladegib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated. 3 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Completed 2, Terminated 1
Phase 11Terminated 1

Follow taladegib: new trials by email Literature Review of taladegib trials Research Report on taladegib

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
ENV-101, Placebo - Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease
Phase 2CompletedEndeavor Biomedicines, Inc.2132024-11-152026-11-17
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
taladegib, placebo - Idiopathic Pulmonary Fibrosis
Phase 2CompletedEndeavor Biomedicines, Inc.412021-08-262024-12-02
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
Carboplatin, External Beam Radiation Therapy, Laboratory Biomarker Analysis - Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma AJCC v7
Phase 1 / Phase 2TerminatedM.D. Anderson Cancer Center72017-03-072023-07-10

Conditions studied

Idiopathic Pulmonary Fibrosis (2)  ·  Pulmonary Fibrosis (2)  ·  Adenocarcinoma Of Esophagus (1)

Sponsors

Endeavor Biomedicines, Inc. (2)  ·  M.D. Anderson Cancer Center (1)

Countries

Australia (2)  ·  Canada (2)  ·  Malaysia (2)  ·  Mexico (2)  ·  South Korea (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Ireland (1)  ·  Italy (1)  ·  New Zealand (1)  ·  United Kingdom (1)  ·  United States (1)

Top investigators

Jaffer A Ajani (1)  ·  John Huetsch, M.D. (1)  ·  Lisa Lancaster, M.D. (1)

Results publications

PMID 41043447